Lymphoma

Videos

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, Discusses Autologous Stem Cell Transplantation for Patients with DLBCL

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCL

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

Armin Ghobadi, MD, on How to Interpret Preliminary Data in Patients with DLBCL

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

Laurie H. Sehn, MD, on the Key Takeaways From the GO29365 Study in DLBCL

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Armin Ghobadi, MD, Discusses Trials Needed to Build on Blinatumomab Pilot Study Data

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

Ghobadi on the Correlation Between CD8/CD4 Ratio and Responses to Blinatumomab in Patients With DLBCL

The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.

Laurie H. Sehn, MD, MPH, Discusses the Extension Arm of the Phase 2 GO29365 Trial in DLBCL

Articles

A recent study found a difference in preference when it came to the administration of rituximab in patients with blood cancer. 

Diffuse Large B-Cell Lymphoma | Topics